Core Insights - HBN, a leading dermatological skincare brand in China, has submitted its listing application to the Hong Kong Stock Exchange, backed by Morgan Stanley and CICC [1] - The company reported a steady revenue growth, achieving RMB 1.514 billion in revenue for the first three quarters of 2025, a year-on-year increase of 10.2%. Net profit is projected to rise from RMB 39 million in 2023 to RMB 129 million in 2024, with a net profit margin reaching 9.6% in the first three quarters of 2025 [1] Group 1: Business Model and Growth Strategy - HBN adopts a "slow" research-driven approach, distinguishing itself from traditional beauty brands, and is increasingly viewed as a model with anti-cyclical characteristics [3] - The global trend towards professional and effective skincare products positions dermatological cosmetics as a key growth driver in the beauty industry [3] - HBN has built a strong technical moat through years of research investment, resulting in over 4.6 million repeat customers, with average repurchase rates of approximately 35.4% on Tmall and 44.0% on Douyin in 2025 [3] Group 2: Research and Development Capabilities - HBN has established a reusable R&D system that encompasses interdisciplinary basic research, ingredient innovation, product development, and a comprehensive multi-dimensional verification system [4] - The R&D team consists of 103 professionals with expertise in various fields, including dermatology and synthetic biology, enabling cross-disciplinary collaboration [6] - HBN has published 50 papers in SCI-indexed journals, ranking first among domestic skincare brands for first-author publications, and has developed innovative ingredients such as the first A-retinol synthesis component approved in China [6] Group 3: Market Position and Future Potential - The valuation logic in the beauty market is shifting towards assessing future value creation capabilities, with HBN's "slow research" model laying the groundwork for significant growth potential [7] - Each research paper, self-developed ingredient, and patent represents a "technical seed" for future growth, potentially leading to breakthrough product solutions and new growth trajectories [7]

Core Insights - HBN, a domestic skincare brand, emphasizes efficacy in its products and has made significant advancements in research and development, showcasing the potential of Chinese brands in scientific innovation [1][3][9] Group 1: Company Overview - HBN was established in 2019 in Shenzhen, focusing on "efficacy skincare" and is the first domestic brand to advocate for true efficacy in skincare products [3] - The brand's R&D center spans over 5,000 square meters and integrates research and production, facilitating rapid validation and application of innovative ideas [3][5] Group 2: Research and Development - HBN has a multidisciplinary R&D team of over 100 members, with 85% holding master's or doctoral degrees, covering fields such as pharmacy, medicine, and computational biology [5] - The company collaborates with over 40 top domestic and international institutions to enhance its technological innovation capabilities [5] Group 3: Achievements in Research - HBN has published 46 international SCI papers as the first author or completing unit, focusing on cutting-edge topics like skin aging mechanisms and whitening activities [7] - The company has successfully registered four self-developed new raw materials, creating a diverse matrix of plant extracts, peptide synthesis, and global innovative ingredients [9] Group 4: Strategic Vision - HBN's CEO emphasizes the importance of foundational research and application transformation in the skincare industry, believing that sustained investment in research will uncover significant user value [9] - The company aims to establish a "research-driven" development path, asserting that Chinese brands can compete with international brands in the high-value efficacy skincare sector [9]